Diagnostic Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence – Final Report Addendum 1

Title: Rapid Tests for Group A Streptococcal infections in people with sore throat

Name of External Assessment Group (EAG) and project lead:

Produced by: Warwick Evidence

Lead author: Hannah Fraser
Co-authors: Daniel Gallacher
Felix Achana
Rachel Court
Sian Taylor-Phillips
Chidozie Nduka
Christopher Stinton
Bex Willans
Paramjit Gill
Hema Mistry

Correspondence to: Dr Hema Mistry

Tel:
Email:
Date completed: 22 May 2019
**Source of funding:**
This report was commissioned by the NIHR HTA Programme as project number NIHR127666.

Sian Taylor-Phillips, Christopher Stinton and Hannah Fraser are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust. Sian Taylor-Phillips is funded by an NIHR Career Development fellowship.

**Declared competing interests of the authors:**
All authors have no conflicts of interest.

**Acknowledgements:**
The authors would like to thank Dr Mitul Patel, Professor Michael Moore, Dr Derren Ready, and Mr Mohammed Rafiq, for their expert clinical advice on searching the literature. We are also grateful to Dr Mitul Patel for expert clinical advice during the clinical effectiveness reviewing and data extraction stages and to Dr Derren Ready for comments on the draft report. The authors would like to thank Karoline Munro for helping with the coordinating of the report.

**Rider on responsibility for report:**
The views expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors.

**This report should be referenced as follows:**
Rapid Tests for Group A Streptococcal infections in people with sore throat. Diagnostic Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Care Excellence.

**Contributions of authors:**
Rachel Court (Information specialist) developed the search strategy and undertook searches. Hannah Fraser (Research Associate), Sian Taylor-Phillips (Associate Professor), Chidozie Nduka (Senior Research Fellow), Christopher Stinton (Senior Research Fellow) and Bex Willans (Academic Foundation 2 doctor) conducted the clinical effectiveness systematic review, this included: screening and retrieving papers, assessing against the inclusion criteria, appraising the quality of papers and abstracting data from papers for synthesis. Daniel Gallacher (Research Fellow) conducted the meta-analyses and contributed to both the clinical and cost-effectiveness sections. Felix Achana (Senior Research Fellow) contributed to the cost-effectiveness review and undertook the health economic modelling. Paramjit Gill (Professor of General Practice) provided clinical guidance and helped
develop the model structures. Hema Mistry (Associate Professor) provided project management, conducted the cost-effectiveness review and supervised the economic analysis. All authors were involved in writing draft and final versions of the report.
Table 1: Base-case cost-effectiveness results update

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Name</th>
<th>Mean costs / 1000 individuals</th>
<th>Mean QALYs / 1000 individuals</th>
<th>Inc. Costs / 1000 individuals</th>
<th>Inc. QALYS / 1000 individuals</th>
<th>ICER versus usual care</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adult primary care model</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>ALERE i Strep A 2 (Abbott)</td>
<td>£56,815</td>
<td>862.82824206</td>
<td>£7,669</td>
<td>0.00365250</td>
<td>£2,099,617</td>
</tr>
<tr>
<td><strong>Adult secondary care model</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>ALERE i Strep A 2 (Abbott)</td>
<td>£56,815</td>
<td>862.82824206</td>
<td>£7,669</td>
<td>0.00365250</td>
<td>£2,099,617</td>
</tr>
<tr>
<td><strong>Children primary care model</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>ALERE i Strep A 2 (Abbott)</td>
<td>£58,405</td>
<td>939.77326996</td>
<td>£8,221</td>
<td>0.003070785</td>
<td>£2,677,054</td>
</tr>
<tr>
<td><strong>Children secondary care model</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>ALERE i Strep A 2 (Abbott)</td>
<td>£58,405</td>
<td>939.77326996</td>
<td>£8,221</td>
<td>0.003070785</td>
<td>£2,677,054</td>
</tr>
</tbody>
</table>

Table 1 shows the four base-case models (adult primary care, adult secondary care, children primary care, children secondary care) using the ID now/formerly ALERE i Strep A 2 test compared with usual care. Even though the test generated more QALYs than usual care, the ICERs were over £2 million.